Douglas Hamilton, MBA
Mr. Hamilton is a Co-Founder and the Chief Executive Officer of i3 Pharmaceuticals, LLC and Pontis Pharma, LLC. Previously, in 2004, he Co-Founded and held the position of President at Synerx Pharma, LLC, a specialty generic pharmaceutical company which was sold to Mylan Laboratories in 2011. Over his 35+ year career, he has held senior executive positions in Sourcing, New Product Development/Commercialization, Manufacturing, and Business Development at leading pharmaceutical companies including Lederle Labs (now Pfizer), Bristol Myers Squibb, Novartis/Sandoz, and Sanofi-Aventis. Mr. Hamilton holds a B.S. degree in Chemical Engineering from the New Jersey Institute of Technology, as well as an M.B.A. from Fairleigh Dickinson University.
Sachin Parate, CFA
Mr. Parate has been a Partner/Owner of a proprietary trading desk specializing in arbitrage opportunities since 2002. He began his career in 1994 at Susquehanna International Group for whom he traded equity derivatives as a market maker, specialist, and lead market maker on the Philadelphia Stock Exchange and Pacific Stock Exchange. He has also built a portfolio of public equity, real estate investments, as well as private debt and equity including Thubrikar Aortic Valve, Inc. He holds a B.S. in Economics with a concentration in Finance from the Wharton School of the University of Pennsylvania.
Tony Zhu, MBA, MBBS, License Partner
Dr. Zhu is the President and Founder of CCRF, a leading Contract Research Organization (CRO) for medical devices focused on interventional cardiology in China. Wide Line Limited is the main shareholder of CCRF. Dr. Zhu has over 20 years of sales, marketing, and management experience in the medical device industry, with specialties in Interventional Cardiovascular, Electrophysiology, and Cardiac Rhythm Management. He has also co-founded start-up companies for interventional cardiology devices and serves as a Board Member to multiple medical companies. Dr. Zhu practiced as a physician specialist in Microbiology and Immunology from 1992-1996, and began his business career in the medical industry in 1996 when he joined Ethicon Wound Closure, Johnson & Johnson Medical, China. He holds an M.B.B.S. from the School of Medicine of Shanghai Jiao Tong University in China, and an M.B.A. from the Lord Ashcroft International Business School of Anglia Ruskin University in the United Kingdom.